Katy Beckermann, MD, PhD
Kathryn Beckermann, MD, PhD, is the Medical Director of GU Clinical Research at Tennessee Oncology. She is a GU medical oncologist specialized in treating kidney, bladder, prostate, and testicular cancer.
Articles by Katy Beckermann, MD, PhD
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
PRO data suggest tivozanib monotherapy maintained quality of life in patients with RCC that progressed after ICI therapy.
The findings from the substudy point to durable antitumor activity for the lenvatinib + belzutifan combination.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.